Biology subjects

Lazzara, M. J.

Publications and source records attributed to Lazzara, M. J..

11 recordsLinked to original sources

bioRxiv2026

Multimodal PET Defines a Goldilocks Thermal Window for Focused Ultrasound Ablation and Immunotherapy Combinations

BackgroundThermally ablative focused ultrasound (T-FUS) offers a noninvasive, spatially precise strategy for local tumor destruction, with the added potential to remodel tumor architecture and immune dynamics in ways that influence downstream therapeutic delivery and efficacy. Despite promising preclinical and clinical findings, the T-FUS parameters that best balance tumor debulking with preservation of local biologic, e.g. immunotherapy, penetrance remain unclear. Thermal dose, defined by the relationship between tissue heating, exposure duration, and biological effect, is likely a critical determinant of this balance. Excessive thermal dose may eliminate the vascular and stromal features needed to support immunotherapy access, whereas insufficient thermal dose may fail to achieve meaningful cytoreduction. Here, we deploy multimodal PET, contrast-enhanced ultrasound, and tissue profiling to define a "Goldilocks Zone" for T-FUS that balances bulk tumor destruction with immunotherapy delivery. MethodSubtotal T-FUS was applied to 4T1 tumors using three thermal dose regimens resolved by in silico modeling. Ablation was quantified by H&E and TTC staining. Post-ablative perfusion and microvascular coverage were assessed by contrast-enhanced ultrasound and immunofluorescence, respectively. Tumor oxygenation was measured by intravenous hypoxyprobe labeling. After T-FUS, mice underwent dynamic [18F]-FDG PET and immunoPET with a model tumor-targeted antibody, [89Zr]-CD47, to relate cytoreduction to antibody penetrance. ImmunoPET findings were further evaluated by ex vivo biodistribution analysis. ResultsIn silico modeling established three T-FUS regimens that generated distinct thermal dose profiles and were deployed in vivo in a solid breast tumor model. Histopathology, perfusion imaging, and hypoxia analysis revealed dose-dependent and dose-divergent biological effects that informed a candidate Goldilocks thermal window. Low thermal dose produced measurable but limited tumor debulking, whereas high thermal dose caused disproportionate functional perfusion collapse. An intermediate thermal dose achieved robust partial ablation, broad hypoxia relief, and preservation of residual tumor physiology sufficient to support antibody access. Dynamic [18F]-FDG PET confirmed a marked reduction in metabolically active tumor burden after Goldilocks T-FUS. Serial [89Zr]-CD47 immunoPET showed that bulk antibody signal was maintained after ablation, and integration of immunoPET with matched [18F]-FDG PET revealed approximately 3-fold enrichment of antibody exposure within the residual viable tumor compartment of ablated tumors. These findings demonstrate that appropriately tuned thermal ablation can debulk tumor while preserving, and potentially concentrating, immunotherapy access within the remaining targetable tumor niche. ConclusionThis study identifies thermal dose as a critical consideration for T-FUS immunotherapy combinations and establishes a PET-informed framework for balancing cytoreduction with therapeutic delivery. Rather than functioning solely as a local debulking modality, we demonstrate that T-FUS can be tuned to yield a post-ablation tumor state that remains accessible to large biologics. These findings provide timely, translationally relevant guidance for tailoring T-FUS regimens to achieve local tumor destruction while preserving an immunotherapy-permissive niche for combination treatment.

bioengineering↗

bioRxiv2026

Systems modeling identifies phenotype-determining signaling pathways controlled by phosphatase PTPRJ in diverse receptor tyrosine kinase activation settings

Protein tyrosine phosphatase receptor J (PTPRJ) restrains cell proliferation and migration by dephosphorylating receptor tyrosine kinases (RTKs) including the epidermal growth factor receptor (EGFR). PTPRJ is a purported tumor suppressor, and alterations to its expression and/or function are associated with colorectal, breast, lung, and other cancers. While there is interest in controlling PTPRJ-regulated phenotypes, efforts are limited by the complexity of PTPRJ-mediated signaling. PTPRJ dephosphorylates multiple RTKs, and the degree to which PTPRJ control of signaling and phenotypes depends on local cellular RTK activation profiles is unknown. To probe the context dependence of PTPRJ signaling regulation, we collected signaling measurements across 16 pathway nodes at two time points in a panel of HSC3 carcinoma cells engineered with different PTPRJ expression profiles. Cells were treated with three different RTK ligands, and paired phenotype measurements (viability, wound healing, xCELLigence cell index) were made. Partial least squares regression models were developed to predict relationships between PTPRJ-regulated signaling pathways and cell phenotypes. The model effectively separated contributions to variance arising from the PTPRJ expression background and growth factor context. In testing model predictions, we demonstrated that PTPRJ suppressed MET-induced cell cell proliferation via regulation of a HER3/AKT signaling axis that stabilized PTPRJ expression through an unanticipated feedback mechanism. We also found that PTPRJ regulated HSC3 cell migration via JNK signaling that was preferentially activated by MET. Our results identify new regulatory nodes through which PTPRJ influences cancer cell phenotypes and demonstrates that these processes preferentially occur in the context of distinct RTK activation states.

systems biology↗

bioRxiv2026

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer

BackgroundPancreatic adenocarcinoma (PDAC) is an abysmal disease, with a poor clinical outcome, largely due to limited life-extending treatments for patients. Notoriously, PDAC displays a T cell-suppressive tumor microenvironment where underlying molecular mechanisms that lead to this phenotype remain poorly understood. To unravel specific mechanisms, we utilized bioinformatic analyses with functional studies and revealed the cytolinker protein plectin (PLEC) as a novel player in regulating the T cell-suppressive tumor microenvironment of PDAC. MethodsUtilizing the TCGA-PAAD dataset, tumor samples were separated by PLEC expression to evaluate patient survival, and pathway analyses associated with increased tumorigenesis. Evaluation of immune infiltration and subsequent immune deconvolution was performed using tidyestimate and CIBERSORTx R packages. Single-cell RNA-seq (scRNA-seq) analysis from 229 PDAC patients was analyzed to investigate signaling dynamics and immune cell infiltration in PLECHigh patients. Functional validation was provided using a monoclonal antibody (mAb) against cell surface plectin (CSP) in two murine PDAC models to examine changes in tumor growth and immune cell subset abundance. ResultsOur studies revealed that high plectin expression results in an overall worse survival associated with activation of pro-tumorigenic pathways and decreased anti-tumor immune signature in PDAC patients. Analysis via GSEA indicates PLECHigh patients display an aggressive phenotype and suppressed pro-inflammatory signaling pathways. Immune ESTIMATE scores were significantly decreased in PLECHigh patients, and scRNA-seq analysis revealed that PLECHigh tumors display a decrease in anti-tumor CD8+ T cells. In vivo analyses using an anti-CSP mAb revealed a reduction in tumor growth kinetics compared to IgG control corresponding with a significant increase in proliferating and activated cytotoxic CD8+ T cells. Anti-CSP-mediated tumor suppression was inhibited when CD8+ T cells were depleted, indicating that anti-CSP treatment is contingent on cytotoxic T cell functionality. ConclusionOur findings identify plectin as a biomarker of aggressive disease in PDAC, with high plectin expression associated with decreased T cell infiltration, and that treatment with anti-CSP mAb reinstates anti-tumor immunity and decreases tumor volume in vivo. These findings position plectin as a high-priority therapeutic target, with the potential to fundamentally reshape immune responses in PDAC and improve outcomes for patients with few remaining options.

cancer biology↗

bioRxiv2025

Systems-level Consequences of Low RAF Abundance for EGFR-ERK Signaling

The RAF kinases are central links between RAS, once activated by receptor tyrosine kinases (RTKs), and the extracellular signal-regulated kinases (ERK). In many cancer cells, RAFs are the least abundantly expressed RTK-ERK pathway proteins and can be present at just hundreds of copies per cell at the plasma membrane, but the consequences of limited RAF expression are unclear. By developing continuum and stochastic computational models of the epidermal growth factor receptor (EGFR)-ERK pathway, we showed that low RAF abundance creates stoichiometric bottlenecks between RTKs and ERK with concomitant stochastic RAF dynamics that propagate to weakly expressed downstream pathway proteins. Advanced sensitivity and Sloppiness analyses identified RAS activation and RAS-RAF interactions as strong determinants of signaling in low-RAF settings and revealed an efficient model fitting approach. RAF bottlenecks were predicted to impede ERK activation by oncogenic RAS mutants and explained a tendency for RAF1 membrane localization to be noisy. This work provides quantitative insight into a common, yet unexplored, regime for EGFR-ERK signaling and a systematic approach to develop and characterize dynamic models of receptor-mediated signaling. STATEMENT OF SIGNIFICANCERAF kinases connect receptors to the mitogenic ERK signaling pathway by translocating to the plasma membrane, but in a substantial fraction of cancer cell contexts RAFs are greatly outnumbered by other pathway proteins, potentially creating an unrecognized and consequential signaling bottleneck. We trained a novel computational model of EGFR-ERK signaling and characterized it comprehensively using integrated multivariate sensitivity analyses and Sloppiness analysis. The results revealed that low RAF abundance suppresses EGFR-mediated ERK activation, limits the effects of upstream oncogenic RAS mutants, and creates stochastic RAF dynamics that can propagate downstream. Thus, the canonical EGFR-ERK pathway exhibits divergent behaviors in a parameter space representative of a substantial fraction of cancer cell settings.

systems biology↗

bioRxiv2025

ERK plays a conserved dominant role in pancreas cancer cell EMT heterogeneity driven by diverse growth factors and chemotherapies

Epithelial-mesenchymal transition (EMT) occurs heterogeneously among malignant carcinoma cells to promote chemoresistance. Identifying the signaling pathways involved will nominate drug combinations to promote chemoresponse, but cell population-level studies are inherently fraught, and single-cell transcriptomics are limited to indirect ontology-based inferences. To understand EMT heterogeneity at a signaling protein level, we combined iterative indirect immunofluorescence imaging of pancreas cancer cells and tumors and mutual information (MI) modeling. Focusing first on MAP kinase pathways, MI predicted that cell-to-cell variation in ERK activity surprisingly dominated control of EMT heterogeneity in response to diverse growth factors and chemotherapeutics, but that JNK compensated when MEK was inhibited. Population-level models could not capture these experimentally validated MI predictions. The dominant role of ERK was predicted by MI even when analyzing seven potential EMT-regulating signaling nodes. More generally, this work provides an approach for studying highly multivariate signaling/phenotype relationships based on protein measurements in any setting.

systems biology↗

bioRxiv2025

Hypoxia-induced histone methylation and NF-κB activation in pancreas cancer fibroblasts promote EMT-supportive growth factor secretion

The pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment contains hypoxic tissue subdomains and cancer-associated fibroblasts (CAFs) of multiple subtypes that play tumor-promoting and -restraining roles. Here, we demonstrate that hypoxia promotes an inflammatory-like CAF phenotype and that hypoxic CAFs selectively promote epithelial-mesenchymal transition (EMT) in PDAC cancer cells through growth factor-mediated cell crosstalk. By analyzing patient tumor single-cell transcriptomics and conducting an inhibitor screen, we identified IGF-2 and HGF as specific EMT-inducing growth factors produced by hypoxic CAFs. We further found that reactive oxygen species-activated NF-{kappa}B cooperates with hypoxia-dependent histone methylation to promote IGF-2 and HGF expression in hypoxic CAFs. In lineage-traced autochthonous PDAC mouse tumors, hypoxic CAFs resided preferentially near hypoxic, mesenchymal cancer cells. However, in subcutaneous tumors engineered with hypoxia fate-mapped CAFs, once-hypoxic re-oxygenated CAFs lacked a spatial correlation with mesenchymal cancer cells. Thus, hypoxia promotes reversible CAF-malignant cell interactions that drive EMT through druggable signaling pathways. One-sentence summaryWe show that hypoxic fibroblasts in pancreas cancer leverage histone methylation and ROS-mediated NF-{kappa}B activation to produce growth factors that drive epithelial-mesenchymal transition in malignant cells, demonstrating how tumor stromal features cooperate to initiate a signaling process for disease progression.

cancer biology↗

bioRxiv2022

A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreas cancer

Here, we show that hypoxia drives especially long-lasting epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) primarily through a positive-feedback histone methylation-MAPK signaling axis. We find that transformed cells preferentially undergo EMT in hypoxic tumor regions in multiple model systems and that hypoxia drives a cell-autonomous EMT in PDAC cells which, unlike EMT in response to growth factors, can last for weeks. We further demonstrate that hypoxia reduces histone demethylase KDM2A activity, suppresses PP2 family phosphatase expression, and activates MAPKs to post-translationally stabilize histone methyltransferase NSD2, leading to an H3K36me2-dependent EMT in which hypoxia-inducible factors play only a supporting role. This mechanism can be antagonized in vivo by combinations of MAPK inhibitors that may be effective in multi-drug therapies designed to target EMT.

cancer biology↗

bioRxiv2021

A reaction-diffusion model predicts the intracellular length scale over which EGFR-initiated GAB1-SHP2 complexes persist

Activation of receptor tyrosine kinases (RTKs) promotes the intracellular assembly of protein complexes formed through phosphotyrosine-SH2 domain linkages. These interactions are weak and reversible, and the dephosphorylation of uncomplexed phosphorylated proteins can be rapid enough to reduce the time and length scales of protein complex persistence distal from the receptor. This limitation may be overcome by cytosolic kinases that rephosphorylate constituent complex proteins as they diffuse. To develop quantitative understanding of the spatiotemporal regulation of these processes, we generated a reaction-diffusion model describing how membrane-bound epidermal growth factor receptor (EGFR) activates the SH2 domain-containing protein tyrosine phosphatase SHP2 by assembling SHP2 complexes with the adaptor GRB2-associated binder 1 (GAB1). Src family kinases (SFKs) were included as a diffusible EGFR-activated intermediary kinase for GAB1. Contrary to the textbook picture of EGFR-mediated SHP2 activation, the model predicts that GAB1-SHP2 complexes can remain intact distal from membrane-retained EGFR at [~]80% of their plasma membrane concentration over the entire intracellular length scale. Parameter sensitivity analysis identified SFK inactivation as one of the most important kinetic processes controlling GAB1-SHP2 spatial persistence, revealing the key role of repeated adaptor phosphorylation in maintaining SHP2 activity. A simple order of magnitude analysis of the controlling rate processes supports the predictions of the coupled differential equation model. Furthermore, proximity ligation assays and immunofluorescence microscopy in carcinoma cells demonstrate that GAB1-SHP2 complexes are increasingly cytoplasmic and distal from EGFR as time proceeds after acute EGFR activation, consistent with model predictions. These results provide quantitative insight into a mechanism that may be alternately tuned for different receptors and downstream effector complexes to enable receptor control of signaling at a distance. STATEMENT OF SIGNIFICANCEThe textbook understanding of receptor-mediated signaling involves the assembly of protein complexes at the receptor cytosolic tail and complex movement within the cell by protein trafficking. However, reaction-diffusion processes can also play an important role in distributing signaling proteins throughout the cell, potentially quite distal from signal-initiating receptors. Indeed, receptors can activate cytosolic kinases that may maintain the phosphorylation-dependent complexation of downstream effector complexes through many rounds of complex dissociation and protein dephosphorylation. Here, we develop quantitative understanding of this mode of signal regulation through development of a mechanistic computational model and demonstrate, with experimental validation, that membrane-bound receptors can regulate signaling through downstream effector complexes over the entire intracellular length scale.

systems biology↗

bioRxiv2021

Agent-Based Model of Multicellular Spheroid Pattern Formation Driven by Synthetic Cell Adhesion Signaling Circuits

Differential adhesion within cell populations enables the emergence of unique patterns in heterogeneous multicellular systems. This process has been previously explored using synthetically engineered heterogenous multicell spheroid systems, in which cell subpopulations engage in bidirectional intercellular signaling to regulate the expression of different cadherins. While engineered cell systems provide excellent experimental tools to observe pattern formation in cell populations, computational models may be leveraged to more systematically explore the key parameters that drive the emergence of different patterns. We developed and validated two- and three-dimensional agent-based models (ABMs) of spheroid patterning for cells engineered with a bidirectional signaling circuit that regulates N- and P-cadherin expression. The model was used to predict how varying initial cell seedings, cadherin induction probabilities, or homotypic adhesion strengths between cells impact spheroid patterning, and unsupervised machine learning techniques were used to map system parameters to unique spheroid patterns. The model was then deployed to design new synthetic cell signaling circuits based on a desired final multicell pattern.

systems biology↗

bioRxiv2020

HGF-induced activation of NEPHRIN and NEPH1 serves as a novel mechanism for recovery of podocytes from injury

When activated, slit diaphragm proteins NEPHRIN and NEPH1 enable signaling pathways leading to podocyte actin cytoskeleton reorganization, which is critical for podocyte recovery from injury. However, the mechanisms through which these proteins are activated remain unknown. This study presents a novel concept showing ligand-induced activation of NEPHRIN and NEPH1. We first identified phosphatase SHP-2, which directly dephosphorylated these proteins. We next identified HGF, a known SHP-2 modulator, as a rapid inducer of NEPHRIN and NEPH1 phosphorylation. Using baculovirus expressed recombinant purified proteins, SPR (surface plasma resonance), molecular modeling and peptide binding approaches, we show that HGF directly binds NEPHRIN and NEPH1 extracellular domains. Further, using cultured podocytes and Drosophila nephrocytes, we demonstrate that while HGF treatment repaired injured podocytes, the addition of inhibitory NEPH1 or NEPHRIN peptides blocked HGF-induced recovery. Overall, this study shows novel activation and deactivation mechanisms for NEPHRIN and NEPH1 that are required for their function.

cell biology↗

bioRxiv2019

Disrupting the Transmembrane Domain Oligomerization of Protein Tyrosine Phosphatase Receptor J Promotes its Activity in Cancer Cells

Despite the critical regulatory roles that receptor protein tyrosine phosphatases (RPTP) play in mammalian signal transduction, the detailed structural basis for the regulation of their catalytic activity is not fully understood, nor are they generally therapeutically targetable. It is due, in part, to the lack of known natural ligands or selective agonists. In contrast to conventional structure-function relationship for receptor tyrosine kinases (RTKs), the activity of RPTPs has been reported to be suppressed by dimerization, which may prevent their access to their RTK substrates. We report here that: (i) homodimerization of PTPRJ (also known as DEP-1) is regulated by specific transmembrane (TM) residues, and (ii) disrupting these interactions can destabilize full-length PTPRJ homodimerization in cells, reduce the phosphorylation of EGFR (a known substrate) and downstream signaling effectors, antagonize EGFR-driven cell phenotypes, and promote substrate access. We demonstrate these points in human cancer cells using both mutational studies and through the identification of a peptide designed to bind to the PTPRJ TM domain. This peptide is the first example of such allosteric agonist of RPTPs. This study, therefore, provides not only fundamental structure-function insights on how PTPRJ activity is tuned by TM interactions in cells but also opportunities to develop a unique class of agents that could be used as tools to probe RPTPs signaling regulating mechanisms or for therapeutic purposes in cancers driven by RTK signaling.

biochemistry↗